EP3740587A1 - Fasoracetam crystalline forms - Google Patents

Fasoracetam crystalline forms

Info

Publication number
EP3740587A1
EP3740587A1 EP19740868.5A EP19740868A EP3740587A1 EP 3740587 A1 EP3740587 A1 EP 3740587A1 EP 19740868 A EP19740868 A EP 19740868A EP 3740587 A1 EP3740587 A1 EP 3740587A1
Authority
EP
European Patent Office
Prior art keywords
fasoracetam
anhydrate
monohydrate
ray powder
peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19740868.5A
Other languages
German (de)
French (fr)
Other versions
EP3740587A4 (en
Inventor
Tom Leyssens
Bram HARMSEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Hospital of Philadelphia CHOP
Original Assignee
Childrens Hospital of Philadelphia CHOP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital of Philadelphia CHOP filed Critical Childrens Hospital of Philadelphia CHOP
Publication of EP3740587A1 publication Critical patent/EP3740587A1/en
Publication of EP3740587A4 publication Critical patent/EP3740587A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • ADHD attention deficit hyperactive disorder
  • mGluR metabotropic glutamate receptor
  • NFC-l fasoracetam
  • Fasoracetam has also been successful in treating subjects having ADHD and 22ql 1.2 Deletion Syndrome (see, e.g., WO2017/044491), anxiety (see, e.g., W02017/044503), conduct disorder (see, e.g., WO2017/044502), Tourette’s syndrome (see, e.g., WO2017/044497), and suggested for treatment of anorexia (see, e.g.,
  • Fasoracetam is orally available and to date has typically been made available as a monohydrate. Fasoracetam has one chiral center and the R-enantiomer has been developed clinically in the form of R-fasoracetam monohydrate Form I. We identified a stable hydrate form (hydrate I), and also a second polymorphic form of the hydrate (hydrate II). Using specific conditions, an anhydrate form could also be isolated.
  • Solid forms of fasoracetam are solid forms of fasoracetam.
  • Various spectroscopic and crystallographic techniques may be used to characterize solid forms of compounds such as, for example, a polymorph, a hydrate, a polymorph of a hydrate, or an anhydrate. These include XRPD, single-crystal x-ray, Raman spectroscopy, infrared spectroscopy, and solid-state NMR spectroscopy, among other techniques.
  • Different solid forms of the same compound often also exhibit distinct thermal behavior. Thermal behavior may be analyzed by such techniques as capillary melting point, thermogravimetric analysis (TGA), and differential scanning calorimetry (DSC) to name a few. These techniques can be used to identify and characterize such solid forms.
  • TGA thermogravimetric analysis
  • DSC differential scanning calorimetry
  • the data from a technique may be used in multiple ways to characterize a solid form.
  • the entire XRPD pattern output from a diffractometer may be used to characterize such a solid form such as, for example, a polymorph, a hydrate, a polymorph of a hydrate, or an anhydrate.
  • a compound is polymorphic if there are two or more crystalline structures of that compound with each crystalline structure being a polymorph of the compound.
  • a smaller subset of such data may also be, and typically is, suitable for such characterization. For example, a collection of one or more peaks from such a pattern may be so used. Indeed, often even a single XRPD peak may be used for such characterization.
  • a solid form herein, or a mixture of solid forms herein is characterized by“one or more peaks” of an XRPD pattern and such peaks are listed, what is meant is that any combination of the peaks listed may be used to characterize the solid form such as, for example, a polymorph, a hydrate, a polymorph of a hydrate, or an anhydrate, or mixture thereof. Further, the fact that other peaks are present in the XRPD pattern, does not negate or otherwise limit the characterization.
  • subsets of spectra of other techniques may be used alone or in combination with other analytical data for characterization purposes.
  • DSC measurements may also be used for such characterization purposes.
  • An XRPD pattern is an x-y graph with °2Q (diffraction angle) on the x-axis and intensity on the y-axis.
  • the pattern contains peaks which may be used to characterize solid forms.
  • the peaks are usually represented and referred to by their position on the x-axis rather than the intensity of peaks on the y-axis because peak intensity can be particularly sensitive to sample orientation (see Pharmaceutical Analysis, Lee & Web, pp. 255-257 (2003)). Thus, intensity is not typically used by those skilled in the pharmaceutical arts to characterize solid forms.
  • Variability also exists in thermal measurements, such as DSC, and may also be indicative of sample purity.
  • Melting point, DSC, and hot stage microscopy alone or in combination with techniques such as x-ray powder diffraction, Raman spectroscopy, infrared spectroscopy or some combination thereof, may be used to characterize cocrystals.
  • typical measurement variability is on the order of l°C.
  • fasoracetam due to the low melting behavior and interactions with water, DSC measurements are reported herein for fasoracetam-containing materials to within 3°C.
  • Form II R-fasoracetam monohydrate is provided.
  • anhydrate R-fasoracetam is provided.
  • “Fasoracetam” as used herein means R-fasoracetam unless otherwise stated:
  • R-Fasoracetam Forms Mixture means a mixture of R-fasoracetam monohydrate Form I, R-fasoracetam monohydrate Form II, and R-fasoracetam anhydrate. This mixture of fasoracetam forms can be prepared, for example in accordance with Example 2.
  • Anhydrate form means the anhydrate form of R-fasoracetam.
  • Figure 1 is an XRPD pattern of R-fasoracetam monohydrate Form I.
  • Figure 2 is a DSC thermogram of R-fasoracetam monohydrate Form I.
  • Figure 3 is a DSC thermogram of R-fasoracetam monohydrate Form I stored under drier conditions compared to ambient conditions.
  • Figure 4 is an XRPD pattern of R-fasoracetam monohydrate Form II.
  • Figure 5 is a DSC thermogram of R-fasoracetam monohydrate Form II.
  • Figure 6 is an overlay of XRPD patterns: (1) R-fasoracetam monohydrate Form II simulated; (2) R-fasoracetam monohydrate Form I simulated; (3) anhydrate R-fasoracetam simulated; (4) Mixture of R-fasoracetam monohydrate Form I, R-fasoracetam monohydrate Form II, and anhydrate R-fasoracetam.
  • Figure 7 is an XRPD pattern of R-fasoracetam anhydrate.
  • Figure 8 is a DSC thermogram of the mixture of R-fasoracetam monohydrate Form I, R-fasoracetam monohydrate Form II, and R-fasoracetam anhydrate.
  • Figure 9 is an overlay of XRPD patterns: (1) Simulated XRPD pattern of R-fasoracetam mononhydrate Form II; (2) XRPD pattern of R-fasoracetam mononhydrate Form II.
  • Figure 10 is an ORTEP drawing of R-fasoracetam monohydrate Form II.
  • Figure 11 is a simulated XRPD pattern of R-fasoracetam monohydrate Form II.
  • Figure 12 is an ORTEP drawing of R-fasoracetam anhydrate.
  • Figure 13 is a simulated XRPD pattern of R-fasoracetam anhydrate.
  • Figure 14 is an overlay of XRPD patterns: (1) Simulated XRPD pattern of R- fasoracetam anhydrate; (2) XRPD pattern of R-fasoracetam anhydrate.
  • Figure 15 is an ORTEP drawing of R-fasoracetam monohydrate Form I.
  • Figure 16 is a simulated XRPD pattern of R-fasoracetam monohydrate Form I.
  • Figure 17 is an overlay of XRPD patterns: (1) XRPD pattern of R-fasoracetam monohydrate Form I; (2) Simulated XRPD pattern of R-fasoracetam monohydrate Form I.
  • Figure 18 is a hydrogen bonding pattern of the anhydrate
  • Figure 19 is a hydrogen bonding pattern of Form I.
  • Figure 20 is a hydrogen bonding pattern of Form II.
  • Figure 21 is an overlay of TGA measurements.
  • Figure 22 is an overlay of DSC measurements.
  • Figure 23 is a hot stage microscope picture of fasoracetam hydrate Form I.
  • Figure 24 is a hot stage microscope picture of fasoracetam hydrate Form II.
  • Figure 25 is a DSC thermogram of R-fasoracetam anhydrate at l0°C/minute.
  • R-fasoracetam monohydrate Form II is provided.
  • This Form II is a polymorph of R-fasoracetam monohydrate Form I in that it has the same chemical composition, but differs in crystal structure.
  • Figure 4 is an XRPD pattern of R- fasoracetam monohydrate Form II and
  • Figure 1 is an XRPD pattern of R-fasoracetam monohydrate Form I.
  • Figure 6 is an overlay XRPD pattern showing the XRPD pattern overlays of Form I, Form II, the anhydrate form of R-fasoracetam, and a mixture thereof.
  • Form II is clearly distinguishable from Form I and the anhydrate. This is confirmed because each of these three solid forms has a different single crystal structure.
  • Form II of R-fasoracetam monohydrate can be characterized by one or more XRPD peaks at about 5.7°20, about 11.3°20, and about 19.4°2Q. There are no peaks at such angles, to within expected variability, in the XRPD pattern of Form I. In addition, one or more of the peaks above may be characterized together with one or more peaks at about 16.7°2Q, and about
  • Form II of R-fasoracetam monohydrate is further characterized by an onset melting point temperature of about 49°C with or without one or more of the XRPD peaks at about 5.7°20, about l l.3°20, and about 19.4°2Q. Additional peaks, such as those at about 16.7°2Q, and about 23.3°20 may be used to characterize Form II.
  • Form II may be characterized by a diffraction pattern substantially the same as that of Figure 11 and/or a DSC thermogram substantially the same as that of Figure 5.
  • R-fasoracetam anhydrate is provided.
  • the anhydrate differs from R-fasoracetam monohydrate Forms I and II in that it lacks water of crystallization as seen in its ORTEP single-crystal representation in Figure 12.
  • This lack of water of crystallization is a characterizing feature of the anhydrate of R-fasoracetam with respect to Form I or Form II.
  • Figure 13 is an XRPD pattern of the anhydrate and any one or more of the peaks in that XRPD pattern may be used to characterize the anhydrate.
  • one or more peaks at about 8.9°2Q, about 13.1°2Q, about 15.2°2Q, about 17.8°2Q, about 18.7°2Q, about 20.3°2Q, and about 22. 2Q may be used to characterize the anhydrate form of R- fasoracetam.
  • the anhydrate has an onset melting temperature at about 94°C.
  • an onset melting point of about 94°C together with one or more peaks at about 8.9°2Q, about 13.1°2Q, about 15.2°2Q, about 17.8°2Q, about 18.7°2Q, about 20.3°2Q, and about 22. 2Q may be used to characterize R-fasoracetam anhydrate.
  • R-fasoracetam anhydrate may be further characterized by a diffraction pattern substantially the same as that of Figure 13.
  • a DSC thermogram of R-fasoracetam anhydrate appears in Figure 25.
  • the ramp rate was at l0°C per minute.
  • the R-fasoracetam anhydrate being hygroscopic, the sample in Figure 25 was obtained by keeping R-fasoracetam monohydrate Form I under vacuum for a prolonged period at a temperature of 65°C.
  • a mixture of Form I, Form II, and anhydrate R-fasoracetam is provided.
  • a mixture of fasoracetam Forms was prepared in Example 2.
  • the mixture may be prepared, for example, by melting Form I and then recrystallizing by cooling.
  • This mixture contains R-fasoracetam Form I, Form II, and the anhydrate form and Figure 6 shows the XRPD pattern of that mixture compared with the simulated pattern of the component parts.
  • XRPD a“simulated” x-ray powder diffraction
  • the XRPD pattern of the mixture is a linear combination of the pure simulated patterns (with varying intensities) which indeed confirms a mixture is present. For example, considering the first 7 peaks of the mixture’s diffraction pattern, those peaks each correspond to a peak in one of the simulated patterns.
  • the peaks at about 5.7°20 and about l l.3°20 correspond to Form II.
  • the peak at about 7.2°20 corresponds to Form I
  • the peaks at about 8.9°2Q, about 12.3°2Q, and about 13.1°2Q correspond to the anhydrate.
  • the peak at about 12.9°q corresponds to Form I, but is also close to the 13.1°2Q in the anhydrate.
  • the Forms may also be characterized by peaks at about 5.7°2Q or about 11 3°2Q or both, and about 7.2°2Q, and one or more of the peaks about 8.9°2Q, about 12.3°2Q, and about 13.1°2Q.
  • the R-fasoracetam Forms Mixture may also be characterized by an onset melting temperature, such as at about 93.5°C, likely corresponding to the melting of the anhydrate present. The endotherm melts at about 54.5°C likely corresponds to Form I.
  • a mixture that has only one of the monohydrate polymorphic forms of R- fasoracetam and the anhydrate.
  • the fasoracetam forms mixture is useful in delivering fasoracetam as a starting material, such as in crystallization experiments to make cocrystals, where it is desirable to limit the amount of water used.
  • pure anhydrate fasoracetam is drier than the mixture, it is difficult to prepare and maintain pure anhydrate fasoracetam without at least some conversion to the monohydrate.
  • compositions containing solid forms or crystalline compounds of fasoracetam as disclosed herein are comprised of one or more pharmaceutically acceptable excipients and a solid form or crystalline material of the disclosure.
  • Such pharmaceutical compositions may be administered orally or configured to be delivered as any effective conventional dosage unit forms, including immediate, slow and timed release oral preparations, parenterally, topically, nasally, ophthalmically, optically, sublingually, rectally, vaginally, and the like.
  • the disclosure further includes methods and uses for treating diseases in humans such as ADHD, 22ql l.2 deletion syndrome, anxiety, conduct disorder, Tourette’s syndrome, and anorexia with effective amount of cocrystals, crystalline compounds, and/or pharmaceutical compositions comprising the cocrystals and/or crystalline compounds of fasoracetam of the disclosure.
  • the subject with ADHD, 22ql l.2 deletion syndrome, anxiety, conduct disorder, Tourette’s syndrome, or anorexia has at least one has at least one copy number variation (CNV) in a metabotropic glutamate receptor (mGluR) network gene (see, e.g., Figures 1-3 of WO2017/044491).
  • CNV copy number variation
  • the mGluR network gene selected from GRM5, GRM8, GRM7, GRM1, NEGR1, SGTB/NLN, USP24, CNTN4, CTNNA2, LARP7, MC4R, SNCA, CA8.
  • Clause 3 The mixture of clause 1, prepared my melting and recry stallizing Form I of R-fasoracetam.
  • Clause 5 The mixture of any one of clauses 1, or 3-4, wherein the mixture has an x-ray powder diffraction pattern comprising one or more peaks chosen from peaks at about 5.7°2Q, about 7.2°2Q, and about 12.9°2Q.
  • Clause 6 The mixture of any one of clauses 1, or 3-4, wherein the mixture has an x-ray powder diffraction pattern comprising one or more peaks chosen from peaks at about 5. 2Q or about 11.3°2Q or both, and about 7.2°2Q, and one or more of the peaks about 8.9°2Q, about 12.3°2Q, and about 13.1 °2Q.
  • Clause 7 The mixture of any one of clauses 1-6, having at least two melting events.
  • Clause 8 The mixture of clause 7, wherein one onset melting temperature is at about 93.5°C.
  • Clause 13 The Form II monohydrate R-fasoracetam of clause 11, wherein Form II has an x-ray powder diffraction pattern comprising a peak at about 11.3°2Q.
  • Clause 14 The Form II monohydrate R-fasoracetam of clause 11, wherein Form II has an x-ray powder diffraction pattern comprising a peak at about 19.4°2Q.
  • Clause 15 The Form II monohydrate R-fasoracetam of any one of clauses 11-14, wherein Form II has an x-ray powder diffraction pattern further comprising one or more peaks chosen from peaks at about 16.7°2Q and about 23.3°2Q.
  • Clause 16 The Form II monohydrate R-fasoracetam of any one of clauses 10-15, wherein Form II has an onset melting temperature of about 49°C.
  • Fasoracetam was ordered from Jinan HaoHua Industry Co., Ltd., and used as received. It was identified via X-ray powder diffraction to be the most stable form of the hydrate (hydrate
  • Peak picking was performed using the WinPLOTR tool available in the commercially available crystallographic tool software known as“FullProf Suite.” Most peak picking was performed using the automatic peak search option with its predefined defaults while some peaks were selected manually.
  • DSC measurements were performed on a DSC 821 METTLER TOLEDO under continuous nitrogen flow. Perforated aluminium crucibles were used for analysis. Onsets were determined by manually constructing a tangent to the peak and a prolongation of the baseline. Total enthalpies were calculated by manual peak integration using a linear interpolation between the initial and final temperatures of integration. To obtain the normalized enthalpy, the total enthalpy was divided by the total sample mass. Ramp rates were typically done at 5°C/minute
  • TGA measurements were carried out on a METTLER TOLEDO TGA/SDTA 85 le. Samples were placed in open aluminum oxide crucible. All experiments were performed under nitrogen flow.
  • Simulated XRPD patterns were calculated from the single crystal structures using the Mercury 3.3 program.
  • the piperidine rings were found to be disordered with the minor fraction ⁇ 10%.
  • the minor part was restrained to be similar (bond and angles) to the main fraction.
  • R-fasoracetam monohydrate Form II was obtained by adding water to 50.69 mg of R- fasoracetam monohydrate Form I (from Aevi Genomics) until total dissolution occurred. The solution was then left to evaporate at room temperature for 21 days after which a crystalline powder was obtained, for which the powder pattern is shown in Figure 4, which contains R- fasoracetam monohydrate Form II and a small amount of Form I.
  • Figure 5 is a DSC thermogram of R-fasoracetam monohydrate Form II containing a small amount of Form I.
  • R-fasoracetam monohydrate Form I was sourced from Jinan Haohua Industry Co., Ltd. and was placed in a round bottom flask and rotavapped for 30 min at 65°C. This procedure has been performed multiple times. In some cases, melting was observed, followed by recrystalbzation at 65°C where the recrystalbzed material is the anhydrate R-fasoracetam. In others, there was no recrystalbzation at 65°C and recrystalbzation only occurred when the temperature was lowered. In those cases, Form I and/or Form II may also crystallize when the melt is taken below the melting points of those forms.
  • the x-ray powder diffraction pattern of the resulting solid typically shows a Fasoracetam Forms Mixture of both Form I and Form II as well as the anhydrate form of R-fasoracetam.
  • Figure 6 shows an overlay of diffraction patterns of the simulated patterns from single crystal solutions of the component R-fasoracetam forms compared with the experimental diffraction pattern of the Fasoracetam Forms Mixture.
  • FIG. 8 is a DSC thermogram of the mixture of R-fasoracetam monohydrate Form I, R-fasoracetam monohydrate Form II, and R-fasoracetam anhydrate.
  • the thermogram shows an onset temperature of about 93.5°C, likely corresponding to the melting of the anhydrate present.
  • the endotherm starting with a shoulder at about 46°C is likely due to the presence of R-fasoracetam monohydrate Form I and/or R-fasoracetam monohydrate Form II.
  • R-fasoracetam monohydrate Form I from Jinan Haohua Industry Co., Ltd. was dissolved in methanol. The solution was then left to slowly evaporate at room temperature to yield a crystalline material.
  • a simulated x-ray powder pattern was prepared from the single crystal data solution and compared with the experimentally obtained powder pattern of Example 1 ( Figure 4) and is shown in Figure 9.
  • An ORTEP drawing is found at Figure 10 and Table 1 is a list of single crystal data parameters.
  • Figure 11 is the simulated XRPD pattern.
  • Example 4 Single Crystal fasoracetam Anhydrate
  • R-fasoracetam monohydrate Form I from Jinan Haohua Industry Co., Ltd. is dissolved in water. The solution was then left to slowly evaporate at room temperature to yield a crystalline material which was analyzed and found to be R-fasoracetam monohydrate Form I.
  • An ORTEP drawing is found at Figure 15, and Table 3 is a list of single crystal data parameters.
  • Figure 16 is a simulated XRPD pattern and Figure 17 is an overlay of the simulated pattern and that of R-fasoracetam monohydrate Form I indicating a match.
  • Table 3 Crystal data and structure refinement for R-fasoracetam monohydrate
  • Figure 18 shows the hydrogen bonding pattern for the anhydrate phase. This
  • bonding network corresponds to an R— (9) synthon (Etter’s graph set notation), composed of a
  • the hydrate form I of fasoracetam ( Figure 19) is a stoichiometric hydrate with one water molecule per fasoracetam molecule.
  • the high number of hydrogen donors and acceptors present create a complex hydrogen bonding network.
  • the water molecules serve as bridge between fasoracetam molecules with both hydrogens forming a bond with a carbonyl group of 2 different pyrrolidone rings.
  • first pyrrolidone ring to the carbonyl on the second leads to a closed-ring R— (8) pattern, which can be seen in the center-bottom of Figure 19.
  • the water molecules can also be seen as molecules that connect different planes.
  • Each water molecule serves as a double hydrogen donor, forming hydrogen bonds with the pyrrolidone carbonyl groups of 2 distinct fasoracetam molecules. Simultaneously, the same water molecule also acts as an acceptor, forming a hydrogen bond with the pyrrolidone N-H group of a third fasoracetam
  • Form I has 10 unique hydrogen bonds and these are made up of hydrogen bonds with water molecules like in Form II, but hydrogen bonds directly between fasoracetam molecules are also present.
  • the increased amount of unique hydrogen bonds together with different hydrogen bond types is the likely reason for the higher stability of Form I.
  • the slight deviation from the ideal stoichiometric ratio can be attributed to the crystallization conditions (the bulk material was obtained from an aqueous solution and the water remaining on the crystal surface or trapped between crystals is likely to cause the deviation observed).
  • the Form II also shows a first onset of weight loss at 4l°C and continues up to l83°C. Analogous to Form I, degradation occurs which starts around 268°C. The observed water loss here is 0.9 equivalent, which is expected for a stoichiometric hydrate.
  • the evaporation continues up until around l85°C, which is in agreement with the data obtained from the TGA.
  • the melting points of Form I and Form II occur prior to the water loss. This indicates that water is lost after melting and one is not dealing with dehydration of the hydrate to yield an amorphous or other anhydrous crystalline form. This is furthermore confirmed visually when the sample is heated to 60°C. As expected, the anhydrate form shows a single melting point, with an onset at 92.6°C. The relatively small difference in melting points between the 2 hydrated forms could suggest that a solid-solid phase transformation can occur.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)

Abstract

The disclosure is directed to crystalline forms and mixtures thereof of R-fasoracetam. Such crystalline forms include Form II monohydrate R-fasoracetam and the anhydrate form of R-fasoracetam. The disclosure further includes mixtures of the anhydrate form of R-fasoracetam together with one or more of Form I monohydrate R-fasoracetam and Form II monohydrate R-fasoracetam.

Description

Fasoracetam Crystalline Forms
[0001] This application claims the benefit of priority to United States Provisional Application No. 62/619,031, filed January 18, 2018; United States Provisional Application No. 62/668,108, filed May 7, 2018; and United States Provisional Application No. 62/683,419, filed June 11, 2018; all of which are incorporated by reference in their entirety.
[0002] Recently, a precision-medicine-based clinical trial was completed reporting successful treatment of attention deficit hyperactive disorder (ADHD) in subjects having at least one genetic alteration in a metabotropic glutamate receptor (mGluR) network gene. In that study, subjects having a genetic alteration in an mGluR network gene were successfully treated with fasoracetam (NFC-l), which has been shown in vitro to be a nonselective activator against all classes of mGluRs (See Hirouchi M, et al. (2000) European Journal of Pharmacology 387:9- 17; see also WO2017/044491). Fasoracetam has also been successful in treating subjects having ADHD and 22ql 1.2 Deletion Syndrome (see, e.g., WO2017/044491), anxiety (see, e.g., W02017/044503), conduct disorder (see, e.g., WO2017/044502), Tourette’s syndrome (see, e.g., WO2017/044497), and suggested for treatment of anorexia (see, e.g.,
PCT/US2017/050228). Fasoracetam is orally available and to date has typically been made available as a monohydrate. Fasoracetam has one chiral center and the R-enantiomer has been developed clinically in the form of R-fasoracetam monohydrate Form I. We identified a stable hydrate form (hydrate I), and also a second polymorphic form of the hydrate (hydrate II). Using specific conditions, an anhydrate form could also be isolated.
[0003] All references disclosed herein are incorporated by reference in their entirety.
[0004] Disclosed herein are solid forms of fasoracetam. Various spectroscopic and crystallographic techniques may be used to characterize solid forms of compounds such as, for example, a polymorph, a hydrate, a polymorph of a hydrate, or an anhydrate. These include XRPD, single-crystal x-ray, Raman spectroscopy, infrared spectroscopy, and solid-state NMR spectroscopy, among other techniques. Different solid forms of the same compound often also exhibit distinct thermal behavior. Thermal behavior may be analyzed by such techniques as capillary melting point, thermogravimetric analysis (TGA), and differential scanning calorimetry (DSC) to name a few. These techniques can be used to identify and characterize such solid forms.
[0005] The data from a technique may be used in multiple ways to characterize a solid form. For example, the entire XRPD pattern output from a diffractometer may be used to characterize such a solid form such as, for example, a polymorph, a hydrate, a polymorph of a hydrate, or an anhydrate. A compound is polymorphic if there are two or more crystalline structures of that compound with each crystalline structure being a polymorph of the compound. A smaller subset of such data, however, may also be, and typically is, suitable for such characterization. For example, a collection of one or more peaks from such a pattern may be so used. Indeed, often even a single XRPD peak may be used for such characterization. When a solid form herein, or a mixture of solid forms herein, is characterized by“one or more peaks” of an XRPD pattern and such peaks are listed, what is meant is that any combination of the peaks listed may be used to characterize the solid form such as, for example, a polymorph, a hydrate, a polymorph of a hydrate, or an anhydrate, or mixture thereof. Further, the fact that other peaks are present in the XRPD pattern, does not negate or otherwise limit the characterization.
[0006] Similarly, subsets of spectra of other techniques may be used alone or in combination with other analytical data for characterization purposes. DSC measurements may also be used for such characterization purposes.
[0007] An XRPD pattern is an x-y graph with °2Q (diffraction angle) on the x-axis and intensity on the y-axis. The pattern contains peaks which may be used to characterize solid forms. The peaks are usually represented and referred to by their position on the x-axis rather than the intensity of peaks on the y-axis because peak intensity can be particularly sensitive to sample orientation (see Pharmaceutical Analysis, Lee & Web, pp. 255-257 (2003)). Thus, intensity is not typically used by those skilled in the pharmaceutical arts to characterize solid forms.
[0008] As with any data measurement, there is variability in x-ray powder diffraction. In addition to the variability in peak intensity, there is also variability in the position of peaks on the x-axis. This variability can, however, typically be accounted for when reporting the positions of peaks for purposes of characterization. Such variability in the position of peaks along the x-axis derives from several sources. One comes from sample preparation. Samples of the same crystalline material, prepared under different conditions may yield slightly different diffractograms. Factors such as particle size, moisture content, solvent content, and orientation may all affect how a sample diffracts x-rays. Another source of variability comes from instrument parameters. Different x-ray instruments operate using different parameters and these may lead to slightly different diffraction patterns from the same crystalline material. Likewise, different software packages process x-ray data differently and this also leads to variability. These and other sources of variability are known to those of ordinary skill in the pharmaceutical arts.
[0009] Due to such sources of variability, it is common to recite x-ray diffraction peaks using the word“about” prior to the peak value in °2Q which presents the data to within 0.1 or 0.2 °2Q of the stated peak value depending on the circumstances. All x-ray powder diffraction peaks cited herein are reported with a variability on the order of 0.2 degree °2Q and are intended to be reported with such a variability whenever disclosed herein whether the word“about” is present or not.
[0010] Variability also exists in thermal measurements, such as DSC, and may also be indicative of sample purity. Melting point, DSC, and hot stage microscopy, alone or in combination with techniques such as x-ray powder diffraction, Raman spectroscopy, infrared spectroscopy or some combination thereof, may be used to characterize cocrystals. With respect to DSC, typical measurement variability is on the order of l°C. However, with regards to fasoracetam, due to the low melting behavior and interactions with water, DSC measurements are reported herein for fasoracetam-containing materials to within 3°C.
SUMMARY
[0011] In one aspect of the disclosure, Form II R-fasoracetam monohydrate is provided.
[0012] In another aspect of the disclosure, anhydrate R-fasoracetam is provided.
[0013] In a further aspect of the disclosure, a mixture of R-fasoracetam forms is provided.
[0014] DEFINITIONS
[0015] “Fasoracetam” as used herein means R-fasoracetam unless otherwise stated:
R-fasoracetam.
[0016]“R-Fasoracetam Forms Mixture” means a mixture of R-fasoracetam monohydrate Form I, R-fasoracetam monohydrate Form II, and R-fasoracetam anhydrate. This mixture of fasoracetam forms can be prepared, for example in accordance with Example 2.
[0017]“Form I” means R-fasoracetam monohydrate Form I.
[0018]“Form II” means R-fasoracetam monohydrate Form II.
[0019] “Anhydrate form” means the anhydrate form of R-fasoracetam.
[0020]“Match” means that to one of ordinary skill in the art, two analytical responses, typically XRPD patterns are the same to within normal expected variability. With respect to the matching analysis, x-axis alignment is significantly more important than y-axis alignment in XRPD patterns due to preferred orientation of crystals and particle statistics. BRIEF DESCRIPTION OF THE FIGURES
[0021] Figure 1 is an XRPD pattern of R-fasoracetam monohydrate Form I.
[0022] Figure 2 is a DSC thermogram of R-fasoracetam monohydrate Form I.
[0023] Figure 3 is a DSC thermogram of R-fasoracetam monohydrate Form I stored under drier conditions compared to ambient conditions.
[0024] Figure 4 is an XRPD pattern of R-fasoracetam monohydrate Form II.
[0025] Figure 5 is a DSC thermogram of R-fasoracetam monohydrate Form II.
[0026] Figure 6 is an overlay of XRPD patterns: (1) R-fasoracetam monohydrate Form II simulated; (2) R-fasoracetam monohydrate Form I simulated; (3) anhydrate R-fasoracetam simulated; (4) Mixture of R-fasoracetam monohydrate Form I, R-fasoracetam monohydrate Form II, and anhydrate R-fasoracetam.
[0027] Figure 7 is an XRPD pattern of R-fasoracetam anhydrate.
[0028] Figure 8 is a DSC thermogram of the mixture of R-fasoracetam monohydrate Form I, R-fasoracetam monohydrate Form II, and R-fasoracetam anhydrate.
[0029] Figure 9 is an overlay of XRPD patterns: (1) Simulated XRPD pattern of R-fasoracetam mononhydrate Form II; (2) XRPD pattern of R-fasoracetam mononhydrate Form II.
[0030] Figure 10 is an ORTEP drawing of R-fasoracetam monohydrate Form II.
[0031] Figure 11 is a simulated XRPD pattern of R-fasoracetam monohydrate Form II.
[0032] Figure 12 is an ORTEP drawing of R-fasoracetam anhydrate.
[0033] Figure 13 is a simulated XRPD pattern of R-fasoracetam anhydrate.
[0034] Figure 14 is an overlay of XRPD patterns: (1) Simulated XRPD pattern of R- fasoracetam anhydrate; (2) XRPD pattern of R-fasoracetam anhydrate.
[0035] Figure 15 is an ORTEP drawing of R-fasoracetam monohydrate Form I.
[0036] Figure 16 is a simulated XRPD pattern of R-fasoracetam monohydrate Form I. [0037] Figure 17 is an overlay of XRPD patterns: (1) XRPD pattern of R-fasoracetam monohydrate Form I; (2) Simulated XRPD pattern of R-fasoracetam monohydrate Form I.
[0038] Figure 18 is a hydrogen bonding pattern of the anhydrate
[0039] Figure 19 is a hydrogen bonding pattern of Form I.
[0040] Figure 20 is a hydrogen bonding pattern of Form II.
[0041] Figure 21 is an overlay of TGA measurements.
[0042] Figure 22 is an overlay of DSC measurements.
[0043] Figure 23 is a hot stage microscope picture of fasoracetam hydrate Form I.
[0044] Figure 24 is a hot stage microscope picture of fasoracetam hydrate Form II.
[0045] Figure 25 is a DSC thermogram of R-fasoracetam anhydrate at l0°C/minute.
DESCRIPTION
[0046] In various embodiments of the disclosure, R-fasoracetam monohydrate Form II is provided. This Form II is a polymorph of R-fasoracetam monohydrate Form I in that it has the same chemical composition, but differs in crystal structure. Figure 4 is an XRPD pattern of R- fasoracetam monohydrate Form II and Figure 1 is an XRPD pattern of R-fasoracetam monohydrate Form I. Figure 6 is an overlay XRPD pattern showing the XRPD pattern overlays of Form I, Form II, the anhydrate form of R-fasoracetam, and a mixture thereof. As can be seen from these figures, Form II is clearly distinguishable from Form I and the anhydrate. This is confirmed because each of these three solid forms has a different single crystal structure.
[0047] Form II of R-fasoracetam monohydrate can be characterized by one or more XRPD peaks at about 5.7°20, about 11.3°20, and about 19.4°2Q. There are no peaks at such angles, to within expected variability, in the XRPD pattern of Form I. In addition, one or more of the peaks above may be characterized together with one or more peaks at about 16.7°2Q, and about
23.3°2Q. [0048] Form II of R-fasoracetam monohydrate is further characterized by an onset melting point temperature of about 49°C with or without one or more of the XRPD peaks at about 5.7°20, about l l.3°20, and about 19.4°2Q. Additional peaks, such as those at about 16.7°2Q, and about 23.3°20 may be used to characterize Form II. Form II may be characterized by a diffraction pattern substantially the same as that of Figure 11 and/or a DSC thermogram substantially the same as that of Figure 5.
[0049] In further embodiments of the disclosure, R-fasoracetam anhydrate is provided. The anhydrate differs from R-fasoracetam monohydrate Forms I and II in that it lacks water of crystallization as seen in its ORTEP single-crystal representation in Figure 12. This lack of water of crystallization is a characterizing feature of the anhydrate of R-fasoracetam with respect to Form I or Form II. Figure 13 is an XRPD pattern of the anhydrate and any one or more of the peaks in that XRPD pattern may be used to characterize the anhydrate. Thus, one or more peaks at about 8.9°2Q, about 13.1°2Q, about 15.2°2Q, about 17.8°2Q, about 18.7°2Q, about 20.3°2Q, and about 22. 2Q may be used to characterize the anhydrate form of R- fasoracetam. The anhydrate has an onset melting temperature at about 94°C. Thus, in another embodiment, an onset melting point of about 94°C together with one or more peaks at about 8.9°2Q, about 13.1°2Q, about 15.2°2Q, about 17.8°2Q, about 18.7°2Q, about 20.3°2Q, and about 22. 2Q may be used to characterize R-fasoracetam anhydrate. R-fasoracetam anhydrate may be further characterized by a diffraction pattern substantially the same as that of Figure 13. A DSC thermogram of R-fasoracetam anhydrate appears in Figure 25. The ramp rate was at l0°C per minute. The R-fasoracetam anhydrate being hygroscopic, the sample in Figure 25 was obtained by keeping R-fasoracetam monohydrate Form I under vacuum for a prolonged period at a temperature of 65°C.
[0050] In additional embodiments, a mixture of Form I, Form II, and anhydrate R-fasoracetam is provided. For example, a mixture of fasoracetam Forms was prepared in Example 2. The mixture may be prepared, for example, by melting Form I and then recrystallizing by cooling. This mixture contains R-fasoracetam Form I, Form II, and the anhydrate form and Figure 6 shows the XRPD pattern of that mixture compared with the simulated pattern of the component parts. With a single crystal x-ray solution, one may also calculate what is called a“simulated” x-ray powder diffraction (“XRPD”) pattern using techniques well known in the art.
[0051] The XRPD pattern of the mixture is a linear combination of the pure simulated patterns (with varying intensities) which indeed confirms a mixture is present. For example, considering the first 7 peaks of the mixture’s diffraction pattern, those peaks each correspond to a peak in one of the simulated patterns. The peaks at about 5.7°20 and about l l.3°20 correspond to Form II. The peak at about 7.2°20 corresponds to Form I, and the peaks at about 8.9°2Q, about 12.3°2Q, and about 13.1°2Q correspond to the anhydrate. The peak at about 12.9°q corresponds to Form I, but is also close to the 13.1°2Q in the anhydrate. Nevertheless, these two peaks between about 12.9°2Q and about 13.1°2Q are accounted for by Form I and the anhydrate. It is also worth noting that the general intensity of the Form I peaks at angles under about 14°2Q are much weaker than Form II and the anhydrate form. The simulated XRPD patterns can be found at Figures 16 (R-fasoracetam Form I), 11 (R-fasoracetam Form II), and 13 (anhydrate R-fasoracetam). Thus, for example, a mixture of fasoracetam Forms may be characterized by peaks at about 5.7°2Q, about 7.2°2Q, and about 12.9°2Q. The Forms may also be characterized by peaks at about 5.7°2Q or about 11 3°2Q or both, and about 7.2°2Q, and one or more of the peaks about 8.9°2Q, about 12.3°2Q, and about 13.1°2Q.
[0052] The R-fasoracetam Forms Mixture may also be characterized by an onset melting temperature, such as at about 93.5°C, likely corresponding to the melting of the anhydrate present. The endotherm melts at about 54.5°C likely corresponds to Form I. In addition to a Forms Mixture, a preparation of a mixture of anhydrate R-fasoracetam with either Form I R- fasoracetam or Form II R-fasoracetam following the general procedures of Example 2. Thus, one may prepare a mixture that has only one of the monohydrate polymorphic forms of R- fasoracetam and the anhydrate.
[0053] The fasoracetam forms mixture is useful in delivering fasoracetam as a starting material, such as in crystallization experiments to make cocrystals, where it is desirable to limit the amount of water used. Although pure anhydrate fasoracetam is drier than the mixture, it is difficult to prepare and maintain pure anhydrate fasoracetam without at least some conversion to the monohydrate.
[0054] This disclosure also relates to pharmaceutical compositions containing solid forms or crystalline compounds of fasoracetam as disclosed herein. Such pharmaceutical compositions are comprised of one or more pharmaceutically acceptable excipients and a solid form or crystalline material of the disclosure. Such pharmaceutical compositions may be administered orally or configured to be delivered as any effective conventional dosage unit forms, including immediate, slow and timed release oral preparations, parenterally, topically, nasally, ophthalmically, optically, sublingually, rectally, vaginally, and the like.
[0055] The disclosure further includes methods and uses for treating diseases in humans such as ADHD, 22ql l.2 deletion syndrome, anxiety, conduct disorder, Tourette’s syndrome, and anorexia with effective amount of cocrystals, crystalline compounds, and/or pharmaceutical compositions comprising the cocrystals and/or crystalline compounds of fasoracetam of the disclosure. In some embodiments, the subject with ADHD, 22ql l.2 deletion syndrome, anxiety, conduct disorder, Tourette’s syndrome, or anorexia has at least one has at least one copy number variation (CNV) in a metabotropic glutamate receptor (mGluR) network gene (see, e.g., Figures 1-3 of WO2017/044491). In some embodiments, the mGluR network gene selected from GRM5, GRM8, GRM7, GRM1, NEGR1, SGTB/NLN, USP24, CNTN4, CTNNA2, LARP7, MC4R, SNCA, CA8.
[0056] The following numbered embodiments are contemplated and are non-limiting: [0057] Clause 1. A mixture of Form I, Form II, and anhydrate R-fasoracetam.
[0058] Clause 2. A mixture of anhydrate R-fasoracetam and Form I or Form II R-fasoracetam.
[0059] Clause 3. The mixture of clause 1, prepared my melting and recry stallizing Form I of R-fasoracetam.
[0060] Clause 4. The mixture of clause 3, wherein the melting was done under partial vacuum.
[0061] Clause 5. The mixture of any one of clauses 1, or 3-4, wherein the mixture has an x-ray powder diffraction pattern comprising one or more peaks chosen from peaks at about 5.7°2Q, about 7.2°2Q, and about 12.9°2Q.
[0062] Clause 6. The mixture of any one of clauses 1, or 3-4, wherein the mixture has an x-ray powder diffraction pattern comprising one or more peaks chosen from peaks at about 5. 2Q or about 11.3°2Q or both, and about 7.2°2Q, and one or more of the peaks about 8.9°2Q, about 12.3°2Q, and about 13.1 °2Q.
[0063] Clause 7. The mixture of any one of clauses 1-6, having at least two melting events.
[0064] Clause 8. The mixture of clause 7, wherein one onset melting temperature is at about 93.5°C.
[0065] Clause 9. The mixture of clauses 7 or 8 wherein the melting is measured by DSC.
[0066] Clause 10. Form II monohydrate R-fasoracetam.
[0067] Clause 11. The Form II monohydrate R-fasoracetam of clause 10, wherein Form II has an x-ray powder diffraction pattern comprising by one or more XRPD peaks chosen from peaks at about 5.7°2Q, about 11.3°2Q, and about 19.4°2Q.
[0068] Clause 12. The Form II monohydrate R-fasoracetam of clause 11, wherein Form II has an x-ray powder diffraction pattern comprising a peak at about 5. 2Q.
[0069] Clause 13. The Form II monohydrate R-fasoracetam of clause 11, wherein Form II has an x-ray powder diffraction pattern comprising a peak at about 11.3°2Q. [0070] Clause 14. The Form II monohydrate R-fasoracetam of clause 11, wherein Form II has an x-ray powder diffraction pattern comprising a peak at about 19.4°2Q.
[0071] Clause 15. The Form II monohydrate R-fasoracetam of any one of clauses 11-14, wherein Form II has an x-ray powder diffraction pattern further comprising one or more peaks chosen from peaks at about 16.7°2Q and about 23.3°2Q.
[0072] Clause 16. The Form II monohydrate R-fasoracetam of any one of clauses 10-15, wherein Form II has an onset melting temperature of about 49°C.
[0073] Clause 17. Form II monohydrate having an x-ray powder diffraction pattern substantially the same as Figure 11.
[0074] Clause 18. Form II monohydrate having a DSC thermogram substantially the same as Figure 5.
[0075] Clause 19. Anhydrate R-fasoracetam.
[0076] Clause 20. The Anhydrate R-fasoracetam of clause 19, wherein the Anhydrate has an x-ray powder diffraction pattern comprising one or more peaks chosen from peaks at about 8.9°2Q, about 13.1°2Q, about 15.2°2Q, about 17.8°2Q, about 18.7°2Q, about 20.3°2Q, and about 22. 2Q.
[0077] Clause 21. The Anhydrate R-fasoracetam of clause 19, wherein the Anhydrate has an x-ray powder diffraction pattern comprising a peak at about 8.9°2Q.
[0078] Clause 22. The Anhydrate R-fasoracetam of clause 19, wherein the Anhydrate has an x-ray powder diffraction pattern comprising a peak at about 13.1°2Q.
[0079] Clause 23. The Anhydrate R-fasoracetam of clause 19, wherein the Anhydrate has an x-ray powder diffraction pattern comprising a peak at about 15.2°2Q.
[0080] Clause 24. The Anhydrate R-fasoracetam of clause 19, wherein the Anhydrate has an x-ray powder diffraction pattern comprising a peak at about 17.8°2Q. [0081] Clause 25. The Anhydrate R-fasoracetam of clause 19, wherein the Anhydrate has an x-ray powder diffraction pattern comprising a peak at about 18.7°2Q.
[0082] Clause 26. The Anhydrate R-fasoracetam of clause 19, wherein the Anhydrate has an x-ray powder diffraction pattern comprising a peak at about 20.3°2Q.
[0083] Clause 27. The Anhydrate R-fasoracetam of clause 19, wherein the Anhydrate has an x-ray powder diffraction pattern comprising a peak at about 22.7°2Q.
[0084] Clause 28. The Anhydrate R-fasoracetam of any one of clauses 19-27, wherein the Anhydrate has an onset melting temperature of about 94°C.
[0085] Clause 29. Anhydrate R-fasoracetam having an x-ray powder diffraction pattern substantially the same as Figure 13.
EXAMPLES
[0086] Materials and Methods
[0087] Fasoracetam was ordered from Jinan HaoHua Industry Co., Ltd., and used as received. It was identified via X-ray powder diffraction to be the most stable form of the hydrate (hydrate
I)·
[0088] All solvents used were obtained from VWR International S.A.S. and used without further purification.
[0089] Instrument Settings
[0090] Two X-ray powder diffraction (XRPD) devices were used to analyze the samples reported herein. Some samples were measured with a Siemens D5000 diffractometer equipped with a Cu X-ray source operating at 40kV and 40 mA and a secondary monochromator allowing to select the Ka radiation of Cu (l = 1.5418 A). A scanning range of 2Q values from
2° to 50°. [0091] Other samples were analyzed with a PANalytical Bragg-Brentano-geometry diffractometer, using Ni-filtered Cu Ka radiation (l = 1.54179 A) at 40 kV and 40 mA with a X’Celerator detector. On this instrument, samples were analyzed between 4 and 50° in 2Q.
[0092] Peak picking was performed using the WinPLOTR tool available in the commercially available crystallographic tool software known as“FullProf Suite.” Most peak picking was performed using the automatic peak search option with its predefined defaults while some peaks were selected manually.
[0093] DSC measurements were performed on a DSC 821 METTLER TOLEDO under continuous nitrogen flow. Perforated aluminium crucibles were used for analysis. Onsets were determined by manually constructing a tangent to the peak and a prolongation of the baseline. Total enthalpies were calculated by manual peak integration using a linear interpolation between the initial and final temperatures of integration. To obtain the normalized enthalpy, the total enthalpy was divided by the total sample mass. Ramp rates were typically done at 5°C/minute
[0094] TGA measurements were carried out on a METTLER TOLEDO TGA/SDTA 85 le. Samples were placed in open aluminum oxide crucible. All experiments were performed under nitrogen flow.
[0095] 1H-NMR spectra were recorded on Bruker-300. ¾-NMR chemical shifts are reported relative to (CD3)2SO (2.5 ppm) or CD3OD (3.3 ppm).
[0096] Single crystal X-ray diffraction was performed on a MAR345 detector using monochromated Mo Ka radiation (l = 0.71073 A)(Xenocs Fox3D mirror) produced by a Rigaku UltraX 18 generator. The data images were integrated by CrysAlisPRO and the implemented multiscan absorption applied. In some cases, an analytical numeric absorption correction was also applied. The structures were solved with SHELXT and then refined on |F2| using SHELXL-2014/7 or SHELXL-2018/1. Nonhydrogen atoms were anisotropically refined. Hydrogen atoms were typically placed in the riding mode with isotropic temperature factors fixed at 1.2 times U(eq) of the parent atoms (1.5 times for methyl groups). Simulated XRPD patterns were calculated from the single crystal structures using the Mercury 3.3 program. For the anhydrate structure, the piperidine rings were found to be disordered with the minor fraction <10%. The minor part was restrained to be similar (bond and angles) to the main fraction.
[0097] The single crystals obtained for SC-XRD analysis were grown via different methods. Initially, fasoracetam (as received, hydrate form I) was recry stallized from water using solvent evaporation. The second hydrate, form II, is less stable and was obtained from methanol evaporation, which provided large enough single crystals. The anhydrate form could not be crystallized from any of the solvents used. To obtain this form, a recrystallization from the melt was performed in vacuo, where it was kept at 60°C for 1 week. These conditions allowed water to be removed from the melt. After a l-week period the temperature was lowered while maintaining vacuum conditions, which resulted in a different solid form, the anhydrate, with crystals suitable for SC-XRD analysis. Starting from hydrates I and II, both convert into the same anhydrated form using the method described above.
[0098] Example 1 - Preparation of R-fasoracetam monohydrate Form II
[0099] R-fasoracetam monohydrate Form II was obtained by adding water to 50.69 mg of R- fasoracetam monohydrate Form I (from Aevi Genomics) until total dissolution occurred. The solution was then left to evaporate at room temperature for 21 days after which a crystalline powder was obtained, for which the powder pattern is shown in Figure 4, which contains R- fasoracetam monohydrate Form II and a small amount of Form I. Figure 5 is a DSC thermogram of R-fasoracetam monohydrate Form II containing a small amount of Form I.
[00100] Example 2 - Preparation of R-fasoracetam Forms Mixture and Anhydrate
[00101] R-fasoracetam monohydrate Form I was sourced from Jinan Haohua Industry Co., Ltd. and was placed in a round bottom flask and rotavapped for 30 min at 65°C. This procedure has been performed multiple times. In some cases, melting was observed, followed by recrystalbzation at 65°C where the recrystalbzed material is the anhydrate R-fasoracetam. In others, there was no recrystalbzation at 65°C and recrystalbzation only occurred when the temperature was lowered. In those cases, Form I and/or Form II may also crystallize when the melt is taken below the melting points of those forms. The x-ray powder diffraction pattern of the resulting solid typically shows a Fasoracetam Forms Mixture of both Form I and Form II as well as the anhydrate form of R-fasoracetam. Figure 6 shows an overlay of diffraction patterns of the simulated patterns from single crystal solutions of the component R-fasoracetam forms compared with the experimental diffraction pattern of the Fasoracetam Forms Mixture.
[00102] To measure the x-ray powder diffractogram of R-fasoracetam anhydrate, the mixture was placed at 80°C. At that temperature, only the pattern of the anhydrate remains, as shown in Figure 7. Figure 8 is a DSC thermogram of the mixture of R-fasoracetam monohydrate Form I, R-fasoracetam monohydrate Form II, and R-fasoracetam anhydrate. The thermogram shows an onset temperature of about 93.5°C, likely corresponding to the melting of the anhydrate present. The endotherm starting with a shoulder at about 46°C is likely due to the presence of R-fasoracetam monohydrate Form I and/or R-fasoracetam monohydrate Form II.
[00103] Example 3 - Single Crystal Preparation of R-fasoracetam monohydrate Form II
[00104] R-fasoracetam monohydrate Form I from Jinan Haohua Industry Co., Ltd. was dissolved in methanol. The solution was then left to slowly evaporate at room temperature to yield a crystalline material. A simulated x-ray powder pattern was prepared from the single crystal data solution and compared with the experimentally obtained powder pattern of Example 1 (Figure 4) and is shown in Figure 9. An ORTEP drawing is found at Figure 10 and Table 1 is a list of single crystal data parameters. Figure 11 is the simulated XRPD pattern. [00105] Table 1 - Crystal data and structure refinement for R-fasoracetam monohydrate
Form II
[00106] Example 4 - Single Crystal fasoracetam Anhydrate
[00107] R-fasoracetam monohydrate Form I from Jinan Haohua Industry Co., Ltd. was placed under vacuum at 60°C and melting was observed. After one week, the temperature was lowered maintaining vacuum conditions. Crystalline material appeared and was found to be R- fasoracetam anhydrate. An ORTEP drawing is found at Figure 12, and Table 2 is a list of single crystal data parameters. Figure 13 is the simulated XRPD pattern and Figure 14 is an overlay of the simulated pattern and that of R-fasoracetam anhydrate. [00108] Table 2 - Crystal data and structure refinement for fasoracetam anhydrate
[00109] Example 5 - Single Crystal of R-fasoracetam monohydrate Form I
[00110] R-fasoracetam monohydrate Form I from Jinan Haohua Industry Co., Ltd. is dissolved in water. The solution was then left to slowly evaporate at room temperature to yield a crystalline material which was analyzed and found to be R-fasoracetam monohydrate Form I. An ORTEP drawing is found at Figure 15, and Table 3 is a list of single crystal data parameters. Figure 16 is a simulated XRPD pattern and Figure 17 is an overlay of the simulated pattern and that of R-fasoracetam monohydrate Form I indicating a match. [00111] Table 3 - Crystal data and structure refinement for R-fasoracetam monohydrate
Form I
[00112] Example 6 - R-fasoracetam Screen
[00113] The three solid forms: Form I, II, and the anhydrate were found in a screen of R-fasoracetam. Initially, a first screen was performed based on the solvent evaporation principle. The purchased compound was dissolved in the solvents investigated and the solution was left to evaporate completely. Once the solution was evaporated completely, the powders obtained from the solvent screen were directly analyzed using XRPD and it was confirmed that they were Form I and Form II as described herein. The results obtained are shown in Table 4. [00114] Table 4 Solvent-based Solid Form Screen for Fasoracetam
[00115] Solvent evaporation did not lead to the formation of R-fasoracetam anhydrate.
The hydrate form obtained from each solvent (Form I or Form II) appears to be random, as no correlation among evaporation rate, hygroscopicity, and polarity were found. Crystals obtained by water and methanol evaporation were found suitable for SC-XRD analysis, which showed a 1 : 1 stoichiometric hydrate form in both cases (Form I and Form II).
[00116] Figure 18 shows the hydrogen bonding pattern for the anhydrate phase. This
2
bonding network corresponds to an R— (9) synthon (Etter’s graph set notation), composed of a
N-H group of the pyrrolidone ring of the first molecule forming a hydrogen bond with the pyrrolidone carbonyl of a second molecule. A second hydrogen bond links the bridging carbonyl of the first molecule to the N-H group in the pyrrolidone ring of the second molecule. This hydrogen bonding pattern is the only pattern present in the crystal structure. [00117] The hydrate form I of fasoracetam (Figure 19) is a stoichiometric hydrate with one water molecule per fasoracetam molecule. The high number of hydrogen donors and acceptors present create a complex hydrogen bonding network. The water molecules serve as bridge between fasoracetam molecules with both hydrogens forming a bond with a carbonyl group of 2 different pyrrolidone rings. A second hydrogen bond from the N-H group on the
2
first pyrrolidone ring to the carbonyl on the second leads to a closed-ring R— (8) pattern, which can be seen in the center-bottom of Figure 19.
[00118] As shown in Figure 19, it is important to note that the water molecule functioning as a double donor lies flat in the plane with both pyrrolidone moieties of the fasoracetam molecules. This interaction, as described above, creates a ring-like arrangement of water and fasoracetam molecules all within the same plane as emphasized by the ball and stick representation. Interestingly, the water molecule serving as a double hydrogen donor in the ring arrangement also acts as an acceptor for a second water molecule, having a proton lying perpendicular to the aforementioned plane. This hydrogen bond connects the different ring-like arrangements in a step-like pattern from an extended point of view. The hydrogen bonds
3
described here can be described as D- (6). Therefore, the water molecules can also be seen as molecules that connect different planes.
[00119] In Figure 20, the hydrogen bonding pattern of the hydrate form II is shown. The main difference between this and the previous hydrate form is the location of the water molecules. All hydrogen bonds he within the same plane, forming a sheet. Contrary to hydrate form I, there are no hydrogen bonds out of the plane, linking the sheets together. Additionally, where in Form I fasoracetam molecules directly form hydrogen bonds with each other, this is not observed in hydrate Form II and all hydrogen bonds go via water molecules. Sheets are therefore held together by interactions other than hydrogen bonding ones, which will likely explain why this hydrate form is less stable, as shown later on. Each water molecule serves as a double hydrogen donor, forming hydrogen bonds with the pyrrolidone carbonyl groups of 2 distinct fasoracetam molecules. Simultaneously, the same water molecule also acts as an acceptor, forming a hydrogen bond with the pyrrolidone N-H group of a third fasoracetam
3 molecule. These interactions connect the whole sheet together and can be described as R- (10).
Crystal structure data tables are further presented below in Table 5 (some data are already present in Tables 1, 2, and 3).
[00120] Table 5 Crystal Structure Data of All Fasoracetam Forms
[00121] As shown by this table, when the Z value for hydrate II is adjusted to one formula unit its volume becomes 286.74 A3. This is slightly bigger than the volume taken by hydrate form I, 282.96 A3. It seems that the reorientation of one of the water molecules for hydrate I results in a slightly more compressed structure as a whole, which could yield stronger (shorter) hydrogen bonds or the formation of new hydrogen bonds due to the molecules’ closer proximity. However, because the data have been collected at different temperatures (150 K for Form II and 297 K for Form I), the difference is likely negligible. When both hydrate forms are compared for the number and composition of hydrogen bonds, the increased stability for Form I becomes apparent. Form II has a total of 5 unique hydrogen bonds, all of them with water molecules. The more stable form, Form I, has 10 unique hydrogen bonds and these are made up of hydrogen bonds with water molecules like in Form II, but hydrogen bonds directly between fasoracetam molecules are also present. The increased amount of unique hydrogen bonds together with different hydrogen bond types is the likely reason for the higher stability of Form I.
[00122] A thermal analysis of all forms was performed in order to characterize the fasoracetam forms and to identify the stability of different forms. TGA measurements (Figure 21) clearly mark the difference between the hydrated and anhydrated form. The anhydrate clearly shows no particular weight loss up until degradation, which occurs at around 260°C. The Form I (blue line), on the other hand, shows a first onset of weight loss at 41 °C. The weight loss continues up to l85°C. When the temperature is increased further, degradation occurs, starting around 260°C. The initial loss corresponds to 1.1 equivalent of water, as expected for a 1: 1 stoichiometric hydrate. The slight deviation from the ideal stoichiometric ratio can be attributed to the crystallization conditions (the bulk material was obtained from an aqueous solution and the water remaining on the crystal surface or trapped between crystals is likely to cause the deviation observed). The Form II also shows a first onset of weight loss at 4l°C and continues up to l83°C. Analogous to Form I, degradation occurs which starts around 268°C. The observed water loss here is 0.9 equivalent, which is expected for a stoichiometric hydrate.
[00123] The DSC measurements (Figure 22) show clear single melting events for all forms, as depicted by the sharp endothermic peaks. In the case of fasoracetam Form II, the onset of the melting point was determined at 47.8°C. For fasoracetam Form I, the onset of the melting point was determined at 57.2°C. This explains that the expected loss in mass starting at 41 °C (TGA measurement) is likely due to surface water. The continuation of mass loss occurs upon melting of the sample. The continued energy input (extended shoulder following the melting peak) after melting suggests that water is evaporating. This finding is supported by the other hydrate, Form II, which exhibits the same behavior. The evaporation continues up until around l85°C, which is in agreement with the data obtained from the TGA. The melting points of Form I and Form II occur prior to the water loss. This indicates that water is lost after melting and one is not dealing with dehydration of the hydrate to yield an amorphous or other anhydrous crystalline form. This is furthermore confirmed visually when the sample is heated to 60°C. As expected, the anhydrate form shows a single melting point, with an onset at 92.6°C. The relatively small difference in melting points between the 2 hydrated forms could suggest that a solid-solid phase transformation can occur. Taking the structural data into account, it would most likely consist of a transformation from a two-dimensional sheet-like hydrogen bonding network (Form II) to a three-dimensional connected sheets hydrogen bonding network. The large difference in melting points between the hydrates and the anhydrate form suggests that conversion of the hydrates into the anhydrate is unlikely at ambient conditions. Investigation of the anhydrate shows that conversion to the stable hydrate occurs at ambient conditions over a l-week period (the conversion was tracked on a daily basis via XRPD). [00124] Using Burger’s Heat of Fusion rule for both hydrated forms (Table 6), they should be monotropically related. Because both hydrates were obtained from different solvents (water and methanol for Forms I and II, respectively), a slurrying experiment where both vials were seeded with the opposite hydrate was performed and left under these conditions for 1 week. After analyzing both vials with XRPD, it turned out that both contained Form I suggesting complete solution mediated polymorphic transition from Form II to Form I. Therefore, we can conclude that Form II is the less stable hydrate.
[00125] Table 6 Enthalpies of Fusion for Fasoracetam Forms
00126] For organic molecules that contain solvent in their form, dehydration or desolvation can occur before or after melting. In the specific case of fasoracetam, melting occurs before dehydration. To verify this, both hydrated forms were placed under a hot stage microscope and pictures proving the melt at the determined melting points have been taken. The pictures for Form I and II can be found in Figures 23 and 24, respectively. The sole purpose of these images is to confirm that melting occurs (as shown via DSC) and no other phase transformations take place.

Claims

What is Claimed is:
1. A mixture of Form I, Form II, and anhydrate R-fasoracetam.
2. A mixture of anhydrate R-fasoracetam and Form I or Form II R-fasoracetam.
3. The mixture of claim 1, prepared my melting and recry stallizing Form I of R- fasoracetam.
4. The mixture of claim 3, wherein the melting was done under partial vacuum.
5. The mixture of any one of claims 1, or 3-4, wherein the mixture has an x-ray powder diffraction pattern comprising one or more peaks chosen from peaks at about 5.7°2Q, about 7.2°2Q, and about 12.9°2Q.
6. The mixture of any one of claims 1, or 3-4, wherein the mixture has an x-ray powder diffraction pattern comprising one or more peaks chosen from peaks at about 5.7°2Q or about 11.3°2Q or both, and about 7.2°2Q, and one or more of the peaks about 8.9°2Q, about 12.3°2Q, and about 13.1°2Q.
7. The mixture of any one of claims 1-6, having at least two melting events.
8. The mixture of claim 7, wherein one onset melting temperature is at about 93.5°C.
9. The mixture of claims 7 or 8 wherein the melting is measured by DSC.
10. Form II monohydrate R-fasoracetam.
11. The Form II monohydrate R-fasoracetam of claim 10, wherein Form II has an x-ray powder diffraction pattern comprising by one or more XRPD peaks chosen from peaks at about 5.7°20, about l l.3°20, and about 19.4°2Q.
12. The Form II monohydrate R-fasoracetam of claim 11, wherein Form II has an x-ray powder diffraction pattern comprising a peak at about 5.7°20.
13. The Form II monohydrate R-fasoracetam of claim 11, wherein Form II has an x-ray powder diffraction pattern comprising a peak at about 11.3°2Q.
14. The Form II monohydrate R-fasoracetam of claim 11, wherein Form II has an x-ray powder diffraction pattern comprising a peak at about 19.4°2Q.
15. The Form II monohydrate R-fasoracetam of any one of claims 11-14, wherein Form II has an x-ray powder diffraction pattern further comprising one or more peaks chosen from peaks at about 16.7°2Q and about 23.3°2Q.
16. The Form II monohydrate R-fasoracetam of any one of claims 10-15, wherein Form II has an onset melting temperature of about 49°C.
17. Form II monohydrate having an x-ray powder diffraction pattern substantially the same as Figure 11.
18. Form II monohydrate having a DSC thermogram substantially the same as Figure 5.
19. Anhydrate R-fasoracetam.
20. The Anhydrate R-fasoracetam of claim 19, wherein the Anhydrate has an x-ray powder diffraction pattern comprising one or more peaks chosen from peaks at about 8.9°20, about 13.1°2Q, about 15.2°2Q, about 17.8°2Q, about 18.7°2Q, about 20.3°20, and about 22.T2Q.
21. The Anhydrate R-fasoracetam of claim 19, wherein the Anhydrate has an x-ray powder diffraction pattern comprising a peak at about 8.9°20.
22. The Anhydrate R-fasoracetam of claim 19, wherein the Anhydrate has an x-ray powder diffraction pattern comprising a peak at about 13.1°2Q.
23. The Anhydrate R-fasoracetam of claim 19, wherein the Anhydrate has an x-ray powder diffraction pattern comprising a peak at about 15.2°2Q.
24. The Anhydrate R-fasoracetam of claim 19, wherein the Anhydrate has an x-ray powder diffraction pattern comprising a peak at about 17.8°2Q.
25. The Anhydrate R-fasoracetam of claim 19, wherein the Anhydrate has an x-ray powder diffraction pattern comprising a peak at about 18.7°2Q.
26. The Anhydrate R-fasoracetam of claim 19, wherein the Anhydrate has an x-ray powder diffraction pattern comprising a peak at about 20.3°2Q.
27. The Anhydrate R-fasoracetam of claim 19, wherein the Anhydrate has an x-ray powder diffraction pattern comprising a peak at about 22.T2Q.
28. The Anhydrate R-fasoracetam of any one of claims 19-27, wherein the Anhydrate has an onset melting temperature of about 94°C.
29. Anhydrate R-fasoracetam having an x-ray powder diffraction pattern substantially the same as Figure 13.
EP19740868.5A 2018-01-18 2019-01-17 CRYSTALLINE FASOR ACETAM SHAPES Pending EP3740587A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862619031P 2018-01-18 2018-01-18
US201862668108P 2018-05-07 2018-05-07
US201862683419P 2018-06-11 2018-06-11
PCT/US2019/014027 WO2019143829A1 (en) 2018-01-18 2019-01-17 Fasoracetam crystalline forms

Publications (2)

Publication Number Publication Date
EP3740587A1 true EP3740587A1 (en) 2020-11-25
EP3740587A4 EP3740587A4 (en) 2021-10-13

Family

ID=67301590

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19740868.5A Pending EP3740587A4 (en) 2018-01-18 2019-01-17 CRYSTALLINE FASOR ACETAM SHAPES

Country Status (12)

Country Link
US (3) US11535604B2 (en)
EP (1) EP3740587A4 (en)
JP (1) JP2021511336A (en)
KR (1) KR20200135771A (en)
CN (1) CN111936463A (en)
AU (1) AU2019209870B2 (en)
BR (1) BR112020014675A2 (en)
CA (1) CA3088970A1 (en)
IL (1) IL276108A (en)
SG (1) SG11202006813TA (en)
WO (1) WO2019143829A1 (en)
ZA (1) ZA202004942B (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2597100A1 (en) 1986-01-21 1987-10-16 Nippon Shinyaku Co Ltd PYROGLUTAMIDE DERIVATIVES
WO1995003801A1 (en) * 1993-07-28 1995-02-09 Nippon Shinyaku Co., Ltd. Antidepressant
US11219617B2 (en) * 2014-05-30 2022-01-11 The Children's Hospital Of Philadelphia Methods of diagnosing and treating autism
PL4023222T3 (en) 2015-09-08 2025-03-24 The Children's Hospital Of Philadelphia Nonselective metabotropic glutamate receptor activator for treatment of 22q syndrome
EP3509640A1 (en) 2016-09-07 2019-07-17 The Children's Hospital of Philadelphia Nonselective metabotropic glutamate receptor activators for treatment of anorexia nervosa and binge eating disorder
KR102877903B1 (en) * 2018-01-18 2025-10-31 더 칠드런스 호스피탈 오브 필라델피아 Solid form of fasoracetam

Also Published As

Publication number Publication date
US12110284B2 (en) 2024-10-08
US20210047288A1 (en) 2021-02-18
SG11202006813TA (en) 2020-08-28
JP2021511336A (en) 2021-05-06
AU2019209870A1 (en) 2020-09-03
KR20200135771A (en) 2020-12-03
ZA202004942B (en) 2023-12-20
AU2019209870B2 (en) 2024-06-13
EP3740587A4 (en) 2021-10-13
BR112020014675A2 (en) 2021-02-17
CN111936463A (en) 2020-11-13
US20230088814A1 (en) 2023-03-23
CA3088970A1 (en) 2019-07-25
IL276108A (en) 2020-08-31
WO2019143829A1 (en) 2019-07-25
US20250129043A1 (en) 2025-04-24
US11535604B2 (en) 2022-12-27

Similar Documents

Publication Publication Date Title
JP5951506B2 (en) Crystalline form of purine derivatives
JP6977185B2 (en) Pyrrolidine compound crystals
CA2963581C (en) Crystal form of bisulfate of jak inhibitor and preparation method therefor
WO2019067591A1 (en) Novel salts and crystals
US12448366B2 (en) Solid forms of pralsetinib
Cavallari et al. Olanzapine solvates
KR102877903B1 (en) Solid form of fasoracetam
TWI449705B (en) 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
US12110284B2 (en) Fasoracetam crystalline forms
JP2015534989A (en) {S-3- (4-Amino-1-oxo-isoindolin-2-yl) (piperidine-3,4,4,5,5-D5) -2,6-dione} solid form
WO2012150183A1 (en) Crystalline sodium salt of an hiv integrase inhibitor
US20260109685A1 (en) Solid forms of pralsetinib
HK40117519A (en) Solid forms of fasoracetam
JP2024515077A (en) Crystalline forms of sphingosine-1-phosphate receptor agonists
WO2017060290A1 (en) Crystalline encenicline hydrochloride
WO2021018387A9 (en) Different forms of 6-chloro-2-ethyl-n-(4-(4-(4-(trifluoromethoxy)phenyl)piperidine-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200811

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40044019

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20210915

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101ALI20210909BHEP

Ipc: C12Q 1/68 20180101AFI20210909BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230908